Trials / Completed
CompletedNCT00243295
Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies
A Pilot Study to Validate the Feasibility of Injecting and Monitoring Recombinant Human Bone Morphogenetic Protein-2/Calcium Phosphate Matrix (rhBMP-2/CPM) in Subjects With Open Wedge Osteotomies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To assess the feasibility of using rhBMP-2/CPM in OWO as a surgical model for pharmacodynamic studies, with assessment of the following parameters: * Injecting the desired volume of rhBMP-2/CPM within the defect * Conducting longitudinal radiographic absorptiometry of the tibial defect in the presence of rhBMP-2/CPM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhBMP-2/CPM |
Timeline
- Start date
- 2003-11-01
- Completion
- 2005-03-01
- First posted
- 2005-10-21
- Last updated
- 2006-10-06
Source: ClinicalTrials.gov record NCT00243295. Inclusion in this directory is not an endorsement.